Aerie Pharmaceuticals, Inc. (AERI) News
Filter AERI News Items
AERI News Results
Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
---|---|---|---|---|---|---|---|---|---|
Loading, please wait... |
AERI News Highlights
- AERI's 30 day story count now stands at 11.
- Over the past 29 days, the trend for AERI's stories per day has been choppy and unclear. It has oscillated between 1 and 3.
- BEAT, DRUG and EBS are the most mentioned tickers in articles about AERI.
Latest AERI News From Around the Web
Below are the latest news stories about Aerie Pharmaceuticals Inc that investors may wish to consider to help them evaluate AERI as an investment opportunity.
Aerie Pharmaceuticals, Inc. (AERI) CEO Raj Kannan on Q4 2021 Results - Earnings Call TranscriptAerie Pharmaceuticals, Inc. (AERI) Q4 2021 Earnings Conference Call February 24, 2022, 17:00 ET Company Participants Hans Vitzthum - LifeSci Advisors Raj Kannan - CEO & Director Michelle Senchyna - Head, Clinical Development and Medical Affairs Jeffrey Calabrese - Director, Accounting Conference Call Participants François Brisebois - Oppenheimer Louise Chen... |
Aerie Pharmaceuticals Non-GAAP EPS of $1.09 beats by $1.77, revenue of $114.7M beats by $83.54MAerie Pharmaceuticals press release (NASDAQ:AERI): Q4 Non-GAAP EPS of $1.09 beats by $1.77. Revenue of $114.7M (+364.4% Y/Y) beats by $83.54M. Outlook: Glaucoma franchise net product revenues: target is $130 million to $140 million, up 16% to 25% versus 2021... |
Aerie Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business UpdateDURHAM, N.C., February 24, 2022--Aerie Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Update |
Aerie Pharmaceuticals Appoints Gary Sternberg, M.D., M.B.A. as Chief Medical OfficerDURHAM, N.C., February 24, 2022--Aerie Pharmaceuticals Appoints Gary Sternberg, M.D., M.B.A. as Chief Medical Officer |
Drug/Biotech Stocks' Q4 Earnings on Feb 24: MRNA, EBS & MoreLet us take a look at five biotech/drug companies, namely, MRNA, EDIT, VIR, EBS and AERI, which are due to release their quarterly results on Feb 24. |
Aerie Pharmaceuticals to Announce Fourth Quarter and Full Year 2021 Financial Results and Host Conference Call on Thursday, February 24, 2022 at 5:00 p.m. ETDURHAM, N.C., February 17, 2022--AERI 4Q & FY21 Save-the-Date |
Aerie Pharmaceuticals (AERI) May Report Negative Earnings: Know the Trend Ahead of Q4 ReleaseAerie (AERI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations. |
Market Sentiment Around Loss-Making Aerie Pharmaceuticals, Inc. (NASDAQ:AERI)With the business potentially at an important milestone, we thought we'd take a closer look at Aerie Pharmaceuticals... |
Analysts Offer Insights on Healthcare Companies: Aerie Pharma (AERI) and Insulet (PODD)Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Aerie Pharma (AERI – Research Report) and Insulet (PODD – Research Report). Aerie Pharma (AERI) Needham analyst Serge Belanger maintained a Buy rating on Aerie Pharma today and set a price target of $22.00. The company's shares closed last Thursday at $6.86, close to its 52-week low of $6.39. According to TipRanks. |
This Teen Retailer Has Doubled in Size in 5 YearsRetail has always been a tough business, so when you see a brand growing fast, you need to dig in and see what's going on -- fast. |